LIMINAL BIOSCIENCES INC (LMNL) Fundamental Analysis & Valuation

NASDAQ:LMNL • CA53272L2021

Current stock price

8.5 USD
+0.01 (+0.12%)
Last:

This LMNL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. LMNL Profitability Analysis

1.1 Basic Checks

  • In the past year LMNL was profitable.
  • In the past year LMNL has reported a negative cash flow from operations.
LMNL Yearly Net Income VS EBIT VS OCF VS FCFLMNL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -50M -100M -150M -200M

1.2 Ratios

  • LMNL has a better Return On Assets (1.46%) than 93.73% of its industry peers.
  • LMNL has a Return On Equity of 2.16%. This is amongst the best in the industry. LMNL outperforms 93.73% of its industry peers.
Industry RankSector Rank
ROA 1.46%
ROE 2.16%
ROIC N/A
ROA(3y)-29.63%
ROA(5y)-80.67%
ROE(3y)-159.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LMNL Yearly ROA, ROE, ROICLMNL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 -400

1.3 Margins

  • With an excellent Profit Margin value of 94.11%, LMNL belongs to the best of the industry, outperforming 99.67% of the companies in the same industry.
  • LMNL does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 94.11%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMNL Yearly Profit, Operating, Gross MarginsLMNL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 2K -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. LMNL Health Analysis

2.1 Basic Checks

  • LMNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, LMNL has about the same amount of shares outstanding.
  • LMNL has a better debt/assets ratio than last year.
LMNL Yearly Shares OutstandingLMNL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
LMNL Yearly Total Debt VS Total AssetsLMNL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

  • LMNL has an Altman-Z score of -45.25. This is a bad value and indicates that LMNL is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -45.25, LMNL is not doing good in the industry: 95.71% of the companies in the same industry are doing better.
  • LMNL has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.02, LMNL is in line with its industry, outperforming 41.09% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -45.25
ROIC/WACCN/A
WACC7.87%
LMNL Yearly LT Debt VS Equity VS FCFLMNL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M -100M

2.3 Liquidity

  • LMNL has a Current Ratio of 2.78. This indicates that LMNL is financially healthy and has no problem in meeting its short term obligations.
  • LMNL has a Current ratio of 2.78. This is in the lower half of the industry: LMNL underperforms 74.75% of its industry peers.
  • A Quick Ratio of 2.78 indicates that LMNL has no problem at all paying its short term obligations.
  • LMNL has a Quick ratio of 2.78. This is in the lower half of the industry: LMNL underperforms 72.94% of its industry peers.
Industry RankSector Rank
Current Ratio 2.78
Quick Ratio 2.78
LMNL Yearly Current Assets VS Current LiabilitesLMNL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. LMNL Growth Analysis

3.1 Past

  • The earnings per share for LMNL have decreased strongly by -99.10% in the last year.
  • LMNL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.92%.
  • LMNL shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -59.99% yearly.
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.93%
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y-59.99%
Sales Q2Q%-28.66%

3.2 Future

  • Based on estimates for the next years, LMNL will show a very negative growth in Earnings Per Share. The EPS will decrease by -230.98% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-907.27%
EPS Next 2Y-230.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LMNL Yearly Revenue VS EstimatesLMNL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
LMNL Yearly EPS VS EstimatesLMNL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 0 10 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. LMNL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 77.27, which means the current valuation is very expensive for LMNL.
  • Compared to the rest of the industry, the Price/Earnings ratio of LMNL indicates a rather cheap valuation: LMNL is cheaper than 93.89% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of LMNL to the average of the S&P500 Index (27.42), we can say LMNL is valued expensively.
  • The Forward Price/Earnings Ratio is negative for LMNL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 77.27
Fwd PE N/A
LMNL Price Earnings VS Forward Price EarningsLMNL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LMNL Per share dataLMNL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

  • A cheap valuation may be justified as LMNL's earnings are expected to decrease with -230.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-230.98%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. LMNL Dividend Analysis

5.1 Amount

  • No dividends for LMNL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

LMNL Fundamentals: All Metrics, Ratios and Statistics

LIMINAL BIOSCIENCES INC

NASDAQ:LMNL (9/25/2023, 8:00:18 PM)

8.5

+0.01 (+0.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08
Earnings (Next)11-07
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.82M
Revenue(TTM)492.00K
Net Income(TTM)463.00K
Analysts43.33
Price Target7.65 (-10%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 77.27
Fwd PE N/A
P/S 55.26
P/FCF N/A
P/OCF N/A
P/B 1.27
P/tB 1.59
EV/EBITDA N/A
EPS(TTM)0.11
EY1.29%
EPS(NY)-8.96
Fwd EYN/A
FCF(TTM)-11.29
FCFYN/A
OCF(TTM)-11.29
OCFYN/A
SpS0.15
BVpS6.71
TBVpS5.33
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 1.46%
ROE 2.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 94.11%
GM N/A
FCFM N/A
ROA(3y)-29.63%
ROA(5y)-80.67%
ROE(3y)-159.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.29%
Cap/Sales 0.61%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.78
Quick Ratio 2.78
Altman-Z -45.25
F-Score4
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)12.21%
Cap/Depr(5y)35.07%
Cap/Sales(3y)46.16%
Cap/Sales(5y)49.99%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.93%
EPS Next Y-907.27%
EPS Next 2Y-230.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y-59.99%
Sales Q2Q%-28.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.94%
OCF growth 3YN/A
OCF growth 5YN/A

LIMINAL BIOSCIENCES INC / LMNL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of LIMINAL BIOSCIENCES INC (LMNL) stock?

ChartMill assigns a fundamental rating of 2 / 10 to LMNL.


What is the valuation status for LMNL stock?

ChartMill assigns a valuation rating of 1 / 10 to LIMINAL BIOSCIENCES INC (LMNL). This can be considered as Overvalued.


What is the profitability of LMNL stock?

LIMINAL BIOSCIENCES INC (LMNL) has a profitability rating of 3 / 10.


What is the valuation of LIMINAL BIOSCIENCES INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for LIMINAL BIOSCIENCES INC (LMNL) is 77.27 and the Price/Book (PB) ratio is 1.27.


Can you provide the expected EPS growth for LMNL stock?

The Earnings per Share (EPS) of LIMINAL BIOSCIENCES INC (LMNL) is expected to decline by -907.27% in the next year.